Depletion of PP2A results in MEK/ERKi resistance in KRAS mutant NSCLC by upregulation of AKT-mTOR signaling and MYC, while PP2A activator DT-061 and MEKi synergistically impair NSCLC growth 157. Here, PTPA is linked to non-small cell lung carcinoma.